Delivering retinal therapies via the suprachoroidal space


Targeted delivery of the therapeutic agent to choroid and retina, with excellent distribution
Potential for longer lasting effect 
Applicable for small and large molecules, gene and cell therapy


Posterior segment reach does not interfere with the visual axis and does not involve the
anterior chamber, minimizing potential side effects (IOP, cataract)



(July 12, 2020)

Everads Therapy featured on European Union's CORDIS website:
The European Union has selected Everads for a publication in the ‘Results in Brief’ section of the European Commission’s CORDIS website.​ 
(read more...)

(March 12, 2020)

Everads Therapy Enters Into Option Agreement With Global Pharma Company to License Everads' Suprachoroidal Delivery System for Retinal Disease Therapies;

- Agreement Supports Potential of Everads' Novel Technology and Method for Delivery of Posterior Segment Therapeutics to the Suprachoroidal Space. (read more...)


This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 882359


The information set forth and the opinions, assumptions and projections contained in this document have been provided in good faith, based on a reasonable belief in its accuracy. However, no assurance can be given that the opinions and assumptions are correct or that any of the projections, expectations or transactions contemplated herein will be attained. All forward looking statements herein involve known and unknown risks, uncertainties and other factors that may cause the actual results and performance of the company to be materially different.

©2018 by Everads Therapy. Proudly created with Wix.com